Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypertriglyceridemia and Cardiovascular Risk Reduction Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APOC3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | APOC3 Recombinant Protein (Wild-Type & Variant Panel including known loss-of-function mutants R19X, A43T). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View APOC3 Products |
| Gene Delivery | APOC3 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Ideal for RNAi/ASO knockdown verification. | View APOC3 Products |
| Benchmark Ab | Anti-APOC3 Monoclonal Antibody (Research Grade). Recombinant neutralizing clone for assay calibration and LPL inhibition rescue assays. | View APOC3 Products |
| Validator | APOC3 siRNA Set (3 unique sequences). For knockdown verification and assay baselining. | View APOC3 Products |
| Related Target: ANGPTL3 | ANGPTL3 Recombinant Protein & Antibodies. Synergistic LPL regulatory pathway; competing therapeutic target. | View ANGPTL3 Products |
| Related Target: APOC2 | APOC2 Recombinant Protein. LPL activator; opposing functional control for assay specificity. | View APOC2 Products |
| Related Target: LPL | Lipoprotein Lipase (LPL) Recombinant Protein. Enzyme substrate for APOC3 inhibition assays. | View LPL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro Knockdown Quantification | High-Purity APOC3 standard proteins for precise custom ELISA construction |
| Cross-species preclinical evaluation (Human/Mouse/Cyno) | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence verified by mass spectrometry |
| Loss-of-function variant validation (R19X, A43T) | Pre-made mutant proteins (Sequence Verified) for negative control establishment and target engagement proof |
| LPL Activity Restoration Assay (Functional neutralization) | Endotoxin-controlled, oligomeric-state characterized recombinant APOC3 suitable for functional LPL inhibition assays |
| Homolog Cross-Reactivity Screening | Sequence Verified APOC1, APOC2, APOC4 proteins for stringent specificity checks |
| False Positives in RNAi Screening | Validated siRNA included for baseline reference and assay standardization |
Live APOC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
APOC3 therapeutics have transitioned from first-generation antisense oligonucleotides (ASOs) to next-generation GalNAc-conjugated siRNAs and long-acting biologics. Ionis Pharmaceuticals established proof-of-concept via volanesorsen (triglyceride reduction >70%), but safety concerns (thrombocytopenia) drove the shift to safer agents. Major players: Arrowhead (Olezarsen, quarterly dosing), Lilly (Dicerna acquisition), and Novo Nordisk exploring ANGPTL3/APOC3 dual-pathway strategies. As first-generation therapies reach Phase 3 for familial chylomicronemia syndrome (FCS), the next wave targets broader cardiovascular risk reduction (ASCVD) and severe hypertriglyceridemia (sHTG). Gene editing (Base Editing, CRISPR) is poised to enter clinical trials for a one-time cure. Future outlook includes combination therapies with statins/PCSK9 inhibitors and expansion into metabolic-associated steatohepatitis (MASH).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| GalNAc-siRNA | Arrowhead (Olezarsen), Lilly | Severe Hypertriglyceridemia, FCS | High-sensitivity target engagement (Need mutant vs WT proteins for selectivity confirmation; need high-purity antigen for ELISA) |
| ASO (First Gen) | Ionis (Volanesorsen), Akcea | Familial Chylomicronemia Syndrome | Species cross-reactivity (Need Cyno/Mouse protein for toxicology bridging) |
| Monoclonal Antibody | Emerging Biotechs | Cardiovascular Risk | LPL inhibition rescue assay (Need purified APOC3+LPL proteins for functional testing) |
| Gene Editing (Preclinical) | Emerging Platforms | Refractory Dyslipidemia | Loss-of-function mimicry (Need variant proteins and stable cell lines for editing efficiency readouts) |